scispace - formally typeset
Open AccessJournal ArticleDOI

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

Reads0
Chats0
TLDR
A paradigm shift in the treatment of selected B-cell malignancies is anticipated, moving from targeting primarily the malignant cells toward combining cytotoxic drugs with agents that interfere with the microenvironment's proactive role.
About
This article is published in Blood.The article was published on 2009-10-15 and is currently open access. It has received 543 citations till now.

read more

Citations
More filters
Journal ArticleDOI

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

TL;DR: The results of the reported clinical trials are reviewed and the progress and key emerging factors that may play a role in effecting tumor responses are discussed, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies.
Journal ArticleDOI

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

TL;DR: It is demonstrated that PCI-32765 effectively inhibits CLL cell migration and survival, possibly explaining some of the characteristic clinical activity of this new targeted agent.
Journal ArticleDOI

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

TL;DR: CAL-101 displays a dual mechanism of action, directly decreasing cell survival while reducing interactions that retain CLL cells in protective tissue microenvironments, and a roadmap for future therapeutic development.
Journal ArticleDOI

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

TL;DR: The data indicate that inhibition of BTK by PCI-32765 overcomes BCR- and chemokine-controlled integrin-mediated retention and homing of malignant B cells in their growth- and survival-supporting lymph node and bone marrow microenvironment, which results in clinically evident CLL regression.
References
More filters
Journal ArticleDOI

Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1.

TL;DR: HK cells protect CLL B cells against apoptosis, at least in part through a CD44-dependent mechanism involving up-regulation of Mcl-1, and this mechanism is distinct from that achieved by CD40 ligation.
Journal ArticleDOI

Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia

TL;DR: Findings support the introduction of CD49d detection in routine prognostic assessment of CLL patients, and suggest both pathogenetic and therapeutic implications for CD 49d expression in CLL.
Journal ArticleDOI

Number of CD4+ Cells and Location of Forkhead Box Protein P3–Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome

TL;DR: Differences in immune cell composition of the diagnostic FL lymph node immune microenvironment have the potential for use as prognostic biomarkers in a routine histopathology setting.
Journal ArticleDOI

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B cell chronic lymphocytic leukemia

TL;DR: CXCR5 plays a role in CLL cell positioning and cognate interactions between CLL and CXCL13-secreting CD68+ accessory cells in lymphoid tissues, and levels correlated with beta2 microglobulin are reported.
Related Papers (5)